Format

Send to

Choose Destination
J Sex Med. 2009 Jul;6(7):1850-6. doi: 10.1111/j.1743-6109.2009.01289.x. Epub 2009 Apr 24.

The incidence of invasive breast cancer among women prescribed testosterone for low libido.

Author information

1
Women's Health Program, Department of Medicine, Central & Eastern Clinical School, Monash University, Alfred Hospital, Prahran, Victoria 3181, Australia. Susan.Davis@med.monash.edu.au

Abstract

INTRODUCTION:

Although the efficacy of testosterone for the treatment of hypoactive sexual desire disorder is well established, the effect of testosterone therapy on breast cancer risk remains uncertain.

AIM:

The incidence of invasive breast cancer among past and current testosterone users.

METHODS:

Retrospective cohort study of 631 women ever treated with testosterone between January 1989 and December 2007 in a clinical endocrinology practice.

MAIN OUTCOME MEASURE:

The incidence of invasive breast cancer since first exposure, and the standardized incidence rate ratio (IRR) calculated using Australian age-specific incidence rates for 2005.

RESULTS:

The mean age of the women at first exposure to testosterone therapy was 49.1 +/- 8.2 years, median treatment duration, 1.3 years, and mean follow-up of 6.7 +/- 4.6 years, providing 4,015 woman-years of follow-up. Twelve cases of invasive breast cancer occurred among 599 women breast cancer-free before treatment, giving an age adjusted IRR of 1.35 (95% confidence interval 0.76-2.38). There was no evidence of an independent effect of duration of exposure on breast cancer risk.

CONCLUSION:

In this study, testosterone use was not associated with a significant increase in breast cancer risk.

Comment in

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center